JP Morgan Maintains Overweight on Neurocrine Biosciences, Lowers Price Target to $176

Neurocrine Biosciences, Inc. +0.06%

Neurocrine Biosciences, Inc.

NBIX

130.00

+0.06%

JP Morgan analyst Anupam Rama maintains Neurocrine Biosciences (NASDAQ: NBIX) with a Overweight and lowers the price target from $177 to $176.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via